Wire · opportunities
Tarsus Pharmaceuticals Acquires Alkeus, Gildeuretinol for Stargardt Disease
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 September 2026 · Fusion42 review
Tarsus Pharmaceuticals acquired Alkeus Pharmaceuticals and its lead asset gildeuretinol, an oral drug in Phase 3 development for Stargardt disease with multiple FDA designations signalling regulatory confidence and unmet medical need. The acquisition leverages Tarsus' existing ophthalmic infrastructure and focuses on the upcoming Phase 3 trial results which will determine the drug's commercial potential.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your eye care biotech startup must track gildeuretinol's Phase 3 trial closely as it tests a novel approach for Stargardt disease, a rare inherited retinal condition with few options. Demonstrating clear clinical benefit will open rare disease commercial opportunities faster than typical drugs due to regulatory designations and Tarsus’ established ophthalmologist network.
◆ Coverage
1 source · 5 Sep 2026
◆ Related on Wire
◆ Topics